VERTEX PHARMACEUTICALS INC / MA 4

EVP Ourania Tatsis received an award of 8,251 restricted stock units of Vertex Pharmaceuticals common stock.

On July 21, 2026, Ourania Tatsis, EVP, Chief Regulatory & Quality Officer of Vertex Pharmaceuticals Incorporated, received an award of 8,251 shares of common stock in the form of restricted stock units that will vest on March 31, 2030, increasing her direct beneficial ownership to 53,572 shares following the grant. The Form 4 reflects this as an acquisition (code A) with no transaction price specified, consistent with a compensatory equity award rather than an open-market purchase. No sales or discretionary purchases were reported in this filing.

Filing Facts

CIK

875320

Ticker

VRTX

Form

4

Source Type

fda

Accession

0000875320-26-000253

Alert Tier

5